Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT01642615
First received: July 12, 2012
Last updated: May 8, 2015
Last verified: May 2015

July 12, 2012
May 8, 2015
July 2012
November 2014   (final data collection date for primary outcome measure)
  • Percentage of Participants Who Experience Each Treatment Emergent Adverse Event Experienced by ≥5% of Participants During the 8-week Healing Treatment Period [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A Treatment Emergent Adverse Event (TEAE) is defined as an Adverse Event (AE) that starts or worsens on or after Study Day 1, and no more than 30 days after the last dose.
  • Percent of Participants Who Experience Each Treatment Emergent Adverse Event Experienced by ≥5% of Participants During the 16-week Maintenance Treatment Period [ Time Frame: From Week 8 to Week 24 ] [ Designated as safety issue: Yes ]
    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A Treatment Emergent Adverse Event (TEAE) is defined as an Adverse Event (AE) that starts or worsens on or after Study Day 1, and no more than 30 days after the last dose.
  • Percent of Participants who Experience Each Treatment Emergent Adverse Event experienced by ≥5% of participants during the 8-week Healing Treatment Period [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
    A Treatment Emergent Adverse Event (TEAE) is defined as an Adverse Event (AE) that starts or worsens on or after Study Day 1, and no more than 30 days after the last dose.
  • Percent of Participants Who Experience Each Treatment Emergent Adverse Event Experienced by ≥5% of Participants During the 16-week Maintenance Treatment Period [ Time Frame: From Week 8 to Week 24 ] [ Designated as safety issue: Yes ]
    A TEAE is defined as an AE that starts or worsens on or after Study Day 1, and no more than 30 days after the last dose.
Complete list of historical versions of study NCT01642615 on ClinicalTrials.gov Archive Site
  • Percentage of Participants With Healing of Erosive Esophagitis (EE) by Week 8 [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    Healing of EE was assessed by endoscopy.
  • Percentage of Participants Who Maintain Healing of EE From Week 8 to Week 24 [ Time Frame: From Week 8 to Week 24 ] [ Designated as safety issue: No ]
    Percentage of participants who maintain healing of EE from Week 8 to Week 24 among the patients who were healed at Week 8 as assessed by endoscopy.
  • Percent of Days With Neither Daytime Nor Nighttime Heartburn Over the First 8 Weeks of Treatment [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    Percent of days with neither daytime nor nighttime heartburn over the first 8 weeks of treatment as assessed by electronic daily diary. The percent of days with neither daytime or nighttime heartburn = (total number of days that are heartburn free)/(total number of days for which either a daytime or nighttime result is marked) x 100%.
  • Percent of Days With Neither Daytime Nor Nighttime Heartburn Over Weeks 8 to 24 [ Time Frame: Weeks 8 to 24 ] [ Designated as safety issue: No ]
    The percent of days with neither daytime nor nighttime heartburn over Weeks 8 to 24 as assessed by electronic daily diary among the participants who were healed at Week 8. The percent of days with neither daytime or nighttime heartburn = (total number of days that are heartburn free)/(total number of days for which either a daytime or nighttime result is marked) x 100%.
  • The percentage of participants with healing of EE by Week 8 [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    Healing of EE will be assessed by endoscopy.
  • The percentage of participants who maintain healing of EE from Week 8 to Week 24 [ Time Frame: From Week 8 to Week 24 ] [ Designated as safety issue: No ]
    The percentage of participants who maintain healing of EE from Week 8 to Week 24 among the patients who were healed at Week 8 as assessed by endoscopy.
  • The percentage of days with neither daytime nor nighttime heartburn over the first 8 weeks of treatment [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    The percentage of days with neither daytime nor nighttime heartburn over the first 8 weeks of treatment as assessed by electronic daily diary.
  • The percentage of days with neither daytime nor nighttime heartburn over Weeks 8 to 24 [ Time Frame: Weeks 8 to 24 ] [ Designated as safety issue: No ]
    The percentage of days with neither daytime nor nighttime heartburn over Weeks 8 to 24 as assessed by electronic daily diary among the participants who were healed at Week 8.
Not Provided
Not Provided
 
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
A Phase 2 Multicenter, 36-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn, in Adolescent Subjects Aged 12 to 17 Years
The purpose of this study is to assess the safety and effectiveness of treatment with once daily oral administration of dexlansoprazole delayed-release capsules in adolescents with erosive esophagitis (EE) and for maintenance of healed EE and relief of heartburn.

The drug being tested in this study is called dexlansoprazole. Dexlansoprazole is being tested to treat adolescents who have erosive esophagitis and heartburn and maintenance of healing of EE.

The study planned to enroll approximately 60 patients.

The study consisted of 3 periods:

  1. Screening ((21 [+5] days)
  2. Treatment (8 weeks for healing, 16 weeks for maintenance),
  3. Post-Treatment Follow-up (up to 3 months).

During screening, participants used an electronic diary (eDiary) daily to document the presence of daytime and nighttime heartburn symptoms and the degree to which heartburn hurt (hereinafter referred to as severity), and to record their use of rescue medication (antacid).

During the first 8 week treatment period, all participants received dexlansoprazole 60 mg, once daily (QD). At the Week 8 visit, participants underwent endoscopy to assess healing of EE. Participants whose EE had not healed were discontinued from the study.

Participants whose EE had healed were randomly assigned (by chance, like flipping a coin) to one of the two treatment groups—which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

  • dexlansoprazole 30 mg QD
  • Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has no active ingredient

All participants were asked to take one tablet each morning without regard to food throughout the study. Throughout both phases of the Treatment Period, all participants continued to use the eDiary to document the presence or absence and severity of daytime and nighttime heartburn symptoms and the use of rescue medication.

This multi-center trial was conducted worldwide. The overall time to participate in this study was 39 weeks. Participants made multiple visits to the clinic, and were contacted by telephone during the study

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Gastroesophageal Reflux Disease
  • Erosive Esophagitis
  • Drug: Dexlansoprazole
    Dexlansoprazole capsules
    Other Name: Dexilant
  • Drug: Placebo
    Dexlansoprazole placebo-matching capsules
  • Experimental: Healing Phase: Dexlansoprazole 60 mg
    Dexlansoprazole 60 mg delayed-release capsules, orally, once daily for up to 8 weeks.
    Intervention: Drug: Dexlansoprazole
  • Experimental: Maintenance Phase: Dexlansoprazole 30 mg
    Participants who are healed at Week 8 will be randomized to receive 30 mg dexlansoprazole delayed-release capsules, orally, once daily for up to 16 weeks.
    Intervention: Drug: Dexlansoprazole
  • Experimental: Maintenance Phase: Placebo
    Participants who are healed at Week 8 will be randomized to receive dexlansoprazole placebo-matching capsules, orally, once daily for up to 16 weeks.
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
63
November 2014
November 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. In the opinion of the investigator, the participant and parent(s) or legal guardian are capable of understanding and complying with protocol requirements.
  2. Prior to any study-specific procedures being performed, the informed consent and the assent form, according to local country requirements, must be signed and dated by parent(s) or legal guardian and by the participant respectively.
  3. The participant has a medical history of symptoms of Gastroesophageal Reflux Disease (GERD) for at least 3 months prior to Screening (signed informed consent form and assent, if applicable) as assessed by the investigator.
  4. The participant has met the electronic diary qualification criteria as assessed by the electronic daily diary defined as follows: heartburn (burning or hurting in your throat, chest, or stomach) on at least 3 of 7 days.(Note: if an endoscopy done within 1 week of signing informed consent and assent is used to confirm diagnosis of EE, the subject does not need to meet this criterion).
  5. The participant has endoscopic evidence of EE (LA Grade A-D) based on the screening endoscopy.
  6. The participant is male or female and aged 12 to 17 years, inclusive.
  7. A male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent and assent throughout the duration of the study and for 30 days after last dose of study medication.
  8. A female participant of childbearing potential who is or may become sexually active agrees to routinely use adequate contraception from the time of signing the informed consent and assent until 30 days after the last dose of study medication.

Exclusion Criteria:

  1. Participant has evidence of cardiovascular, pulmonary, central nervous system, hepatic, hematopoietic, renal, metabolic, endocrine or gastrointestinal disease, or serious allergy, asthma, or allergic skin rash that suggests clinically significant, uncontrolled underlying disease or condition (other than the disease being studied), which may impact the ability of the participant to participate or potentially confound the study results.
  2. The participant has a co-existing disease affecting the esophagus (eg, esophageal varices, scleroderma, viral or fungal infection, or esophageal stricture), history of radiation therapy or cryotherapy to the esophagus, caustic or physiochemical trauma such as sclerotherapy to the esophagus.
  3. The participant has known history of Barrett's with dysplastic changes in the esophagus.
  4. The participant has a known history of eosinophilic esophagitis (EoE) or endoscopic findings suggestive of EoE.
  5. The participant has a history of celiac disease or participant tests positive for tissue transglutaminase (tTG) antibody.
  6. The participant has active gastric or duodenal ulcers within 4 weeks prior to Day -1.
  7. Participant has any finding in his/her medical history, physical examination, or safety clinical laboratory tests giving reasonable suspicion of underlying disease that might interfere with the conduct of the trial.
  8. Participant has taken any proton pump inhibitor (PPI) within 1 week (7 days) prior to the Screening Visit.
  9. Participant tests positive for H. pylori.
  10. The participant has a history of hypersensitivity or allergies to dexlansoprazole or any component of dexlansoprazole or any PPI (including lansoprazole, omeprazole, rabeprazole, pantoprazole, or esomeprazole) or antacid containing Mg(OH)2 and/or Al(OH)3 or simethicone.
  11. The participant is required to take excluded medications or it is anticipated that the participant will require treatment with at least one of the disallowed concomitant medications during the study evaluation period as specified in the Excluded Medications and Treatments Section 7.3.
  12. The participant has a history of malignant disease (except basal cell carcinoma) within 5 years prior to Screening.
  13. The participant has a condition that may require inpatient surgery during the course of the study.
  14. The participant requires dilatation of esophageal strictures and/or strictures preventing passage of the endoscope during the Screening endoscopy. Schatzki's ring (a ring of mucosal tissue near the lower esophageal sphincter) is acceptable.
  15. The participant is known to be human immunodeficiency virus (HIV) positive.
  16. The participant has current or clinical history of Zollinger-Ellison syndrome or other hypersecretory condition.
  17. The participant has a history of gastric, duodenal or esophageal surgery except simple oversew of an ulcer. A history of gastric tube and/or percutaneous endoscopic gastrostomy (PEG) placement is allowed.
  18. The participant had an acute upper gastrointestinal hemorrhage within 4 weeks prior to endoscopy.
  19. The participant has donated or lost ≥300 mL blood volume, undergone plasmapheresis, or has had a transfusion of any blood product within 90 days prior to the first dose of study drug.
  20. The participant has a known history of alcohol abuse or illegal drug use within the past 12 months prior to the first dose of study drug.
  21. The participant has any Screening Visit 1 abnormal laboratory value that suggests a clinically significant underlying disease or condition that may prevent the participant from entering the study; or the participant has: creatinine >1.5 mg/dL, alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >2 times the upper limit of normal (×ULN), or total bilirubin >2.0 mg/dL with AST/ALT elevated above the limits of normal values.
  22. If female, the participant is pregnant or lactating or intending to become pregnant before, during or within 30 days after last dose of study medication; or intending to donate ova during such time period.
  23. If male, the participant intends to donate sperm during the course of this study or within 30 days after last dose of study drug.
  24. The participant, participant's Parent(s) or Legal Guardian is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in the conduct of this study or may consent and assent under duress. Students of the institution/research facility who are under the supervision of, or in a subordinate role to, the investigator are also ineligible.
  25. The participant or participant's Parent(s) or Legal Guardian, in the opinion of the investigator, is unlikely to comply with the protocol requirements or is unsuitable for any other reason.
  26. The participant has participated in another clinical study and/or has received any investigational compound within 30 days prior to Screening.
Both
12 Years to 17 Years   (Child)
No
Contact information is only displayed when the study is recruiting subjects
United States,   Belgium,   Brazil,   Hungary,   Italy,   Mexico,   Poland,   Portugal
 
NCT01642615
TAK-390MR_207, U1111-1128-6117, 2012-001681-15
No
Not Provided
Not Provided
Takeda
Takeda
Not Provided
Study Director: Medical Director, Clinical Science Takeda Global Research and Development Center, Inc.
Takeda
May 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP